戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  Adverse events were similar for placebo and fremanezumab.
2 manezumab, and four (1%) of 285 with monthly fremanezumab.
3 nti-CGRP monoclonal antibody (anti-CGRP-mAb) fremanezumab.
4 ients were randomized 1:1 to receive monthly fremanezumab (225 mg) or matched placebo.
5 e-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab o
6   All patients in the OLE received quarterly fremanezumab (675 mg).
7 nvestigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP antibody, in patien
8                                              Fremanezumab, a humanized monoclonal antibody targeting
9  was -5.1 (0.50; 95% CI, -6.09 to -4.13) for fremanezumab and -2.9 (0.49; 95% CI, -3.89 to -1.96) for
10  was -6.0 (0.55; 95% CI, -7.10 to -4.95) for fremanezumab and -4.6 (0.54; 95% CI, -5.66 to -3.55) for
11                                         Both fremanezumab and placebo were administered by means of s
12 ith placebo, two (<1%) of 276 with quarterly fremanezumab, and four (1%) of 285 with monthly fremanez
13                                              Fremanezumab as a preventive treatment for chronic migra
14                               Treatment with fremanezumab compared with placebo resulted in significa
15                              We compared two fremanezumab dose regimens with placebo for the preventi
16 atic function occurred in 5 patients in each fremanezumab group (1%) and 3 patients in the placebo gr
17 al nociceptors as a likely site of action of fremanezumab in the prevention of headache.
18 n 3 patients), erenumab (in 5 patients), and fremanezumab (in 1 patient).
19  The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons
20 l arteries, which was effectively blocked by fremanezumab, it did not induce dilatation in pial arter
21 n [LSM] change -0.6 [SE 0.3]) with quarterly fremanezumab (LSM change -3.7 [0.3]; LSM difference vs p
22 CI -3.8 to -2.4]; p<0.0001) and with monthly fremanezumab (LSM change -4.1 [0.34]; LSM difference vs
23 ogy to subcutaneously administered quarterly fremanezumab (month 1, 675 mg; months 2 and 3: placebo),
24 1, 675 mg; months 2 and 3: placebo), monthly fremanezumab (month 1: 225 mg in episodic migraine and 6
25 g at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at w
26  with fremanezumab quarterly, 4.6+/-0.3 with fremanezumab monthly, and 2.5+/-0.3 with placebo (P<0.00
27 y assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo.
28 the fremanezumab-quarterly group, 41% in the fremanezumab-monthly group, and 18% in the placebo group
29 52%) were eligible and randomized to receive fremanezumab (n = 175) or placebo (n = 178).
30 domly assigned to placebo (n=279), quarterly fremanezumab (n=276), or monthly fremanezumab (n=283).
31 , quarterly fremanezumab (n=276), or monthly fremanezumab (n=283).
32 action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked
33                                              Fremanezumab pretreatment selectively inhibited the resp
34     In addition, when given sufficient time, fremanezumab prevents the activation and sensitization o
35  days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single dose of 675 mg at basel
36 ents enrolled, 376 were randomly assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and
37 f headache days per month was 4.3+/-0.3 with fremanezumab quarterly, 4.6+/-0.3 with fremanezumab mont
38 er of headache days per month was 38% in the fremanezumab-quarterly group, 41% in the fremanezumab-mo
39       The long-term durability and safety of fremanezumab require further study.
40 ral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, a
41 dy was to better understand how the CGRP-mAb fremanezumab (TEV-48125) modulates meningeal sensory pat
42             We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of
43 l dilatation or PPE by CSD, the inability of fremanezumab to prevent them suggests that these events
44    Adverse events were consistent with other fremanezumab trials.
45                                              Fremanezumab was effective and well tolerated in patient
46 dural arteries and PPE are all unaffected by fremanezumab, whereas the brief constriction and prolong